The study of tauopathies is challenged by the complexity of the tau protein itself, the clinical and molecular heterogeneity of tauopathies, the need for early diagnostic biomarkers, and species differences that limit the translation of preclinical discoveries into clinical practice. The gene discussed is MAPT; the disease is tauopathy.